Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ibiglustat (GZ402671) 是一种可透过血脑屏障的、具有口服活性的葡萄糖神经酰胺合成酶(GCS)抑制剂。它可用于戈谢病 3 型、法布瑞氏症、与 GBA 突变相关的帕金森病、GM2 神经节苷脂病和常染色体显性多囊肾病的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 566 | 现货 | ||
2 mg | ¥ 828 | 现货 | ||
5 mg | ¥ 1,790 | 现货 | ||
10 mg | ¥ 2,730 | 现货 | ||
25 mg | ¥ 4,580 | 现货 | ||
50 mg | ¥ 6,530 | 现货 | ||
100 mg | ¥ 8,890 | 现货 | ||
500 mg | ¥ 17,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,560 | 现货 |
产品描述 | Ibiglustat (GZ402671) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. Ibiglustat blocks the formation of glucosylceramide (GL-1), a key intermediate in the synthesis of GL-3. Ibiglustat is potentially useful for treating Fabry disease. Fabry disease is a rare lysosomal storage disorder, which results in abnormal tissue deposits of a particular fatty substance called globotriaosylceramide (GL-3 or Gb3) throughout the body. |
体外活性 | Ibiglustat is in phase II Clinical trials for the treatment of Fabry's disease. Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for α-galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy [1]. |
别名 | Venglustat, SAR402671, GZ402671 |
分子量 | 389.49 |
分子式 | C20H24FN3O2S |
CAS No. | 1401090-53-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (128.37 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5675 mL | 12.8373 mL | 25.6746 mL | 64.1865 mL |
5 mM | 0.5135 mL | 2.5675 mL | 5.1349 mL | 12.8373 mL | |
10 mM | 0.2567 mL | 1.2837 mL | 2.5675 mL | 6.4187 mL | |
20 mM | 0.1284 mL | 0.6419 mL | 1.2837 mL | 3.2093 mL | |
50 mM | 0.0513 mL | 0.2567 mL | 0.5135 mL | 1.2837 mL | |
100 mM | 0.0257 mL | 0.1284 mL | 0.2567 mL | 0.6419 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ibiglustat 1401090-53-6 Metabolism Transferase oral Parkinson's disease Venglustat GZ-402671 inhibit SAR402671 Inhibitor GBA SAR 402671 SAR-402671 GZ 402671 Fabry disease GL-3 levels GZ402671 mutations inhibitor